Health Catalyst Issues Q2 Revenue Guidance of $68M-$70M
HCAT sits 47% above its 52-week low of $0.955 on light trading volume (0.3× avg).
Summary
Health Catalyst has provided its second-quarter revenue guidance, projecting figures between $68 million and $70 million. This guidance is a significant forward-looking financial update, especially following the company's recent 10-K/A filing on April 30, which detailed substantial underperformance against key growth metrics in 2025 and led to executive and board changes. Traders will closely monitor how this guidance aligns with market expectations and provides insight into the company's near-term financial trajectory after a challenging previous year. Future catalysts will include the actual Q2 earnings report and any further strategic updates.
At the time of this announcement, HCAT was trading at $1.40 on NASDAQ in the Technology sector, with a market capitalization of approximately $101.5M. The 52-week trading range was $0.96 to $4.74. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.